1. Home
  2. NXG vs NERV Comparison

NXG vs NERV Comparison

Compare NXG & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NXG NextGen Infrastructure Income Fund of Beneficial Interest

NXG

NXG NextGen Infrastructure Income Fund of Beneficial Interest

HOLD

Current Price

$58.84

Market Cap

301.9M

Sector

N/A

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$6.19

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXG
NERV
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.9M
301.6M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
NXG
NERV
Price
$58.84
$6.19
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.50
AVG Volume (30 Days)
61.4K
174.5K
Earning Date
01-01-0001
05-01-2026
Dividend Yield
14.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.05
$1.30
52 Week High
$58.99
$12.46

Technical Indicators

Market Signals
Indicator
NXG
NERV
Relative Strength Index (RSI) 66.57 47.60
Support Level $47.61 $5.83
Resistance Level N/A $6.69
Average True Range (ATR) 1.15 0.50
MACD 0.49 -0.04
Stochastic Oscillator 89.21 20.00

Price Performance

Historical Comparison
NXG
NERV

About NXG NXG NextGen Infrastructure Income Fund of Beneficial Interest

Cushing NextGen Infrastructure Income Fund is a closed-end management investment company. Its investment objective is to seek a high total return with an emphasis on current income. The fund invests at least 80% of its net assets in a portfolio of equity and debt securities of infrastructure companies, including energy infrastructure companies, industrial infrastructure companies, sustainable infrastructure companies and technology and communication infrastructure companies.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: